Payment overview · 2025
General Payments
$503.96
23 reported records · 11 companies
Healthcare provider profile · identity verified
Mechery Davis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WARWICK, RI · NPI 1407824477
Verified facts
What the public records show
CMS Open Payments records show Mechery Davis, MD received $503.96 in general payments during 2025 across 23 reported records.
Phathom Pharmaceuticals, Inc. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.22 | 17.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.46 | 17.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.70 | 12.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.09 | 10.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.28 | 9.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.33 | 9.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.23 | 7.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.02 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.70 | 3.5% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.30 | 3.2% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $13.63 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $503.96 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $88.22 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $86.46 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.09 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.28 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $48.33 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 608 | 147 |
| Omeprazole | Omeprazole | 305 | 72 |
| Lisinopril | Lisinopril | 302 | 81 |
| Alprazolam | Alprazolam | 296 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 249 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 44 |
| Gabapentin | Gabapentin | 192 | 36 |
| Metformin Hcl | Metformin Hcl | 182 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 40 |
| Losartan Potassium | Losartan Potassium | 149 | 30 |
| Atenolol | Atenolol | 147 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 36 |
| Glipizide Er | Glipizide | 133 | 29 |
| Simvastatin | Simvastatin | 129 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 27 |
| Furosemide | Furosemide | 93 | 20 |
| Ozempic | Semaglutide | 92 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 23 |
| Tramadol Hcl | Tramadol Hcl | 72 | 11 |
| Ibuprofen | Ibuprofen | 69 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | suppressed |
| Famotidine | Famotidine | 67 | 19 |
| Trazodone Hcl | Trazodone Hcl | 67 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 62 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Eliquis | Apixaban | 57 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 57 | 16 |
| Jardiance | Empagliflozin | 55 | suppressed |
| Potassium Chloride | Potassium Chloride | 54 | 15 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Allopurinol | Allopurinol | 51 | 13 |
| Azithromycin | Azithromycin | 49 | 42 |
| Baclofen | Baclofen | 48 | suppressed |
| Chlorthalidone | Chlorthalidone | 48 | 11 |
| Metformin Hcl Er | Metformin Hcl | 48 | 15 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Clotrimazole | Clotrimazole | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Oxycontin | Oxycodone Hcl | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | suppressed |
| Prednisone | Prednisone | 23 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Nystatin | Nystatin | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $503.96 · 23 records | Phathom Pharmaceuticals, Inc. | AIRSUPRA, Cologuard Collection Kit, Doc Band, EVENITY, FREESTYLE LIBRE 3, MOUNJARO, PAXLOVID, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, WELLBUTRIN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error